EUVIMEDEUVIMED entdecken
Crossref

METTL14-dependent regulation of HMGB1 attenuates inflammation in diabetic retinopathy

Zhangxin Huang, Jitian Guan, Xue Zhang, Qiang Hu, Jiayang Huang, Wei Sang, Xiaoning Wang, Bo Jiang, Dawei Sun

Acta Diabetologica · 2025

DOI: 10.1007/s00592-025-02623-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Diabetologica, 2025. Verfasst von Zhangxin Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. Hauptthemen laut MEDLINE: HMGB1 Protein, Diabetic Retinopathy, Methyltransferases, Inflammation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Diabetic retinopathy (DR) is a frequent complication of diabetes, characterized by progressive vision loss, with chronic inflammation being an important contributor in its development. N6-methyladenine (m6A) is a crucial RNA modification within eukaryotes, playing an essential role in different bodily functions and disease states. Nonetheless, the precise mechanism underlying m6A modification in DR remains elusive. METHODS: BV2 cells were stimulated with high glucose (HG) and mice were injected intraperitoneally with streptozotocin (STZ) to induce inflammation. RT-qPCR, Western blot, ELISA, immunofluorescence, CCK-8, Wound Healing, and RIP assays were used to evaluate the effects of methyltransferase-like 14 (METTL14) in these models. RESULTS: Our study indicated significantly decreased levels of METTL14 in HG stimulated BV2 cells and in STZ models. In addition, METTL14 levels were reduced in peripheral venous samples of DR patients. Meanwhile, the inflammatory factors were inhibited by up-regulation of METTL14 in HG stimulated BV2 cells and STZ models. Mechanistically, METTL14 overexpression inhibited high mobility group box 1 (HMGB1), thereby suppressing nuclear factor kappa-B (NF-κB) signaling pathway activation. CONCLUSION: This study suggested that METTL14 may influence inflammation in DR by modulating the HMGB1/NF-κB pathway, providing valuable insights into potential therapeutic approaches for DR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HMGB1 ProteinDiabetic RetinopathyMethyltransferasesInflammationAnimalsMiceHumansMaleDiabetes Mellitus, ExperimentalMice, Inbred C57BLNF-kappa BSignal TransductionCell Line

Stichwörter der Autor:innen

Diabetic retinopathyHigh mobility group protein 1InflammationMethyltransferase-like 14m6A modification

Substanzen

HMGB1 ProteinMethyltransferasesMETTL14 protein, humanNF-kappa BHMGB1 protein, mouse

Autor:innen und Institutionen

  • Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
  • Future Medical Laboratory, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
  • Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. sundawei@hrbmu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, Z., Guan, J., Zhang, X., Hu, Q., Huang, J., Sang, W., Wang, X., Jiang, B., & Sun, D. (2025). METTL14-dependent regulation of HMGB1 attenuates inflammation in diabetic retinopathy. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02623-y

Vancouver

Huang Z, Guan J, Zhang X, Hu Q, Huang J, Sang W, et al. METTL14-dependent regulation of HMGB1 attenuates inflammation in diabetic retinopathy. Acta Diabetologica. 2025. doi:10.1007/s00592-025-02623-y

BibTeX
@article{Huang2025,
  author = {Huang, Zhangxin and Guan, Jitian and Zhang, Xue and Hu, Qiang and Huang, Jiayang and Sang, Wei and Wang, Xiaoning and Jiang, Bo and Sun, Dawei},
  title = {METTL14-dependent regulation of HMGB1 attenuates inflammation in diabetic retinopathy},
  journal = {Acta Diabetologica},
  year = {2025},
  doi = {10.1007/s00592-025-02623-y}
}
Kostenlos starten →